Latest Annual Report
Filed: 2026-02-06
Key Insights
- The company reported strong revenue growth across its key product segments, including its anti-CD20 therapeutic programs and Alzheimer's collaboration.
- Biogen made strategic acquisitions, such as Reata Pharmaceuticals and HiBio, which could expand its pipeline and drive future growth.
- The company's operating expenses, including selling, general and administrative expenses as well as amortization and impairment of acquired intangible assets, have increased, which could impact profitability.